Jacobs Levy Equity Management Inc. Takes Position in Cryoport, Inc. (NASDAQ:CYRX)

Jacobs Levy Equity Management Inc. bought a new position in Cryoport, Inc. (NASDAQ:CYRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 73,537 shares of the company's stock, valued at approximately $572,000. Jacobs Levy Equity Management Inc. owned approximately 0.15% of Cryoport as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in shares of Cryoport by 1,464.4% during the third quarter. JPMorgan Chase & Co. now owns 305,237 shares of the company's stock worth $2,475,000 after acquiring an additional 285,726 shares during the last quarter. Avanza Fonder AB purchased a new stake in shares of Cryoport during the fourth quarter worth about $64,000. SG Americas Securities LLC grew its stake in shares of Cryoport by 44.8% during the fourth quarter. SG Americas Securities LLC now owns 146,789 shares of the company's stock worth $1,142,000 after acquiring an additional 45,430 shares during the last quarter. Penbrook Management LLC grew its stake in shares of Cryoport by 6.0% during the fourth quarter. Penbrook Management LLC now owns 52,570 shares of the company's stock worth $409,000 after acquiring an additional 2,975 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Cryoport by 2.9% during the fourth quarter. Rhumbline Advisers now owns 63,284 shares of the company's stock worth $492,000 after acquiring an additional 1,764 shares during the last quarter. 92.90% of the stock is currently owned by institutional investors.

Cryoport Stock Performance

NASDAQ CYRX traded down $0.18 during trading hours on Friday, reaching $6.04. The stock had a trading volume of 253,099 shares, compared to its average volume of 543,684. The stock has a fifty day moving average of $5.93 and a 200 day moving average of $6.82. The stock has a market cap of $302.83 million, a P/E ratio of -1.79 and a beta of 1.92. Cryoport, Inc. has a 52-week low of $4.58 and a 52-week high of $11.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70.

Cryoport (NASDAQ:CYRX - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The business had revenue of $41.04 million for the quarter, compared to analyst estimates of $56.19 million. Sell-side analysts predict that Cryoport, Inc. will post -0.99 earnings per share for the current year.

Insiders Place Their Bets

In other Cryoport news, CEO Jerrell Shelton sold 4,620 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the sale, the chief executive officer now owns 765,399 shares in the company, valued at approximately $4,814,359.71. This represents a 0.60% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 19,830 shares of company stock worth $118,353. Corporate insiders own 10.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on CYRX shares. Roth Mkm restated a "buy" rating and set a $15.00 price target on shares of Cryoport in a research note on Tuesday, April 1st. Guggenheim reiterated a "buy" rating and issued a $10.00 target price on shares of Cryoport in a research report on Wednesday, April 16th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 target price on shares of Cryoport in a research report on Thursday, May 8th. Morgan Stanley dropped their target price on Cryoport from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Finally, UBS Group upped their target price on Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a research report on Tuesday, April 1st. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, Cryoport has an average rating of "Moderate Buy" and an average price target of $11.00.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.